BioSpace News Archive

Enteris BioPharma, Inc., a biotechnology company developing innovative drug products based on its proprietary delivery technologies, and a wholly-owned subsidiary of SWK Holdings Corporation, announced that the company will participate in DCAT® Week 2022 being held March 21-24, 2022 in New York City.

OrthoGrid® Systems, Inc., is pleased to announce the OrthoGrid Hip AI application. Powered by artificial intelligence and machine learning, our Hip AI platform is the world’s first-ever intraoperative hip replacement navigation system.

SCYNEXIS, Inc. (NASDAQ: SCYX), a biotechnology company pioneering innovative medicines to overcome and prevent difficult-to-treat and drug-resistant infections, today announced its participation in three in-person medical conferences and one virtual investor panel in March.

Creative Medical Technology Holdings, Inc. announced the appointment of Sahil Nock as the Company’s Chief Commercial Officer, effective February 28, 2022.

RegeneRx Biopharmaceuticals, Inc. (OTCQB: RGRX) (“RegeneRx”), a clinical-stage drug development company focused on tissue protection, repair and regeneration has posted information released by HLB Therapeutics in Korea pursuant to the pre-BLA meeting with the FDA on February 28, 2022.

AM-Pharma B.V., an emerging leader focused on developing therapeutics for severe medical conditions, announced that members of its senior management team are scheduled to participate in the following investor conferences.

Thermo Fisher Scientific’s PPD clinical research business has been named a winner in Training magazine’s 2022 Training APEX Awards, recognizing its robust enterprise learning programs designed to grow employees’ skills and drive customers’ success.

Hillstream BioPharma, Inc. (NASDAQ: HILS) (“Hillstream” or the “Company”), a biotechnology company developing novel therapeutic candidates targeting ferroptosis, an emerging new anti-cancer mechanism resulting in iron mediated cell death for drug resistant and devastating cancers, provided a webcast replay of the Company’s R&D Day held on February 24, 2022.

Shattuck Labs, Inc. (Shattuck) (NASDAQ: STTK), a clinical-stage biotechnology company pioneering the development of bi-functional fusion proteins as a new class of biologic medicine for the treatment of patients with cancer and autoimmune disease, today announced that company management will participate in two virtual investor conferences in March 2022.

Capricor Therapeutics announced the expansion of its Senior Leadership team with the appointment of Daniel Paulson, M.D. as Vice President of Clinical Development.